CJC-1295 NO DAC
Modified GRF terminology
“CJC-1295 NO DAC” is a market term that must be distinguished from CJC-1295 with DAC.
Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.
Identity not confirmed
The name may refer to different substance or product forms.
“CJC-1295 NO DAC” is not a sufficiently specific chemical identity: sequence, modification and salt must be documented for the product. It is not automatically Mod GRF 1-29.
Research areas
Evidence matrix
- Molecular identity
- Partially clarified
“CJC-1295 NO DAC” is not a sufficiently specific chemical identity: sequence, modification and salt must be documented for the product. It is not automatically Mod GRF 1-29.
- Human research
- None
- Replication
- No independent replication
- Clinical endpoints
- No clinical endpoints
- Safety
- Not adequately studied
- Approval
- No documented approval
The dimensions are presented separately and are not combined into an overall score.
What the source shows
FDA documents describe different forms and inconsistent nomenclature.
- FDA PCAC: CJC-1295 forms and nomenclatureRegulatory source2024
U.S. Food and Drug Administration
Accessed:
Research gaps
- ·Data and half-life for the DAC form cannot automatically be assigned to “NO DAC”.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
Mechanism
The term concerns GHRH-related compounds without the DAC moiety. Exact chemical identity must be established.
- FDA PCAC: CJC-1295 forms and nomenclatureRegulatory source2024
U.S. Food and Drug Administration
Accessed:
Study protocols
No sufficiently supported, exactly citable study protocols are available.
Calculator
Arithmetic based only on your entries. Not a dose or use recommendation.
Reported adverse effects
- ·Safety has not been adequately studied.
Contraindications and warnings
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Interactions
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Research gaps
- ·Data and half-life for the DAC form cannot automatically be assigned to “NO DAC”.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
- FDA PCAC: CJC-1295 forms and nomenclatureRegulatory source2024
U.S. Food and Drug Administration
Accessed:
Sources
Sources checked: · Version 2
- FDA PCAC: CJC-1295 forms and nomenclatureRegulatory source2024
U.S. Food and Drug Administration
Accessed: